Stories From

Bozeman & Beyond

Berra Yazar-klosinski

psychedelic therapy for PTSD, sleep, and more

At the non-profit MAPS (Multidisciplinary Association for Psychedelic Studies), Berra Yazar-Klosinskihe oversees research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. In this episode, we hear more about how various psychedelics- such as MDMA and cannabis- have been successful in treating Post Traumatic Stress Disorder (or PTSD), sleep disorders, and more.

Berra Yazar-Klosinski, Ph.D., is an employee of the 501(c)(3) non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) with a dual appointment as the Chief Scientific Officer of MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of MAPS. Dr. Yazar-Klosinski is responsible for development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.

After gaining experience in clinical research laboratories with Geron Corporation and Millennium Pharmaceuticals, Dr. Yazar-Klosinski joined MAPS in 2009 to work with an organization where profit wouldn’t dictate the agenda of scientific research. Over the last 10 years, she has supported MAPS clinical research and regulatory affairs through all stages of growth. Dr. Yazar-Klosinski has developed a strong track record of success with FDA, state regulatory agencies and multiple regulatory agencies outside of the USA.

Dr. Yazar-Klosinski earned her B.S. in Biology with a minor in Drama from Stanford University and her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She is a Turkish hunter-gatherer who is supporting the growth of her family and pets in harmony with the natural world as she works tirelessly to transform the future.

Open Access articles related to MAPS research
Phase 3 trial of MDMA-assisted therapy for PTSD
Phase 2a trial of Cannabis for PTSD

MDMA & Sleep:
MDMA alters the response of the circadian clock to a photic and non-photic stimulus

Time of MDMA administration in Monkeys influences effects on sleep

MDMA improves self-reported sleep quality in PTSD patients with durable effects when administered at least 10 hrs before bedtime (10am)

In healthy volunteers, MDMA facilitated participants’ reported ability to more readily fall asleep when administered 14 hrs before bedtime

Pittsburgh Sleep Quality Index

Berra’s recommended books & resources:
Power of Attachment (Diane Poole Heller)
Consciousness Medicine (Francoise Bourzat)
This Is Your Mind on Plants (Michael Pollan)
TED Talk on Why I Train Grandmothers to Treat Depression (Dixon Chibanda)

Recent Podcasts


on writing, teaching, exploring

John McPhee was born in Princeton, New Jersey, and was educated at Princeton University and Cambridge University. After seven years at Time magazine, he moved to The New Yorker, where he has been a staff writer since 1965. A Fellow of the Geological Society of America and a member of the American Academy of Arts and Letters, he was awarded in 1999 the Pulitzer Prize for General Nonfiction (Annals of the Former World).